V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10008613 | 10005429 | null | null | Palliative (P) | 2016-10-31 | 2017-03-04 | Nintedanib | 02 | N | 10244555 | FEC + DOCETAXEL |
| 10008614 | 10005432 | 1.76 | 0 | Curative (C) | 2018-07-06 | 2018-09-29 | Obinutuzumab | 2 | N | 10245324 | CETUXIMAB |
| 10008615 | 10005435 | null | 52.7 | Palliative (P) | 2018-08-03 | 2018-08-24 | BUSULFAN | 02 | N | 10245610 | CLADRIBINE |
| 10008616 | 10005438 | 0 | 83.2 | Palliative (P) | 2017-09-04 | 2017-09-09 | Bortezomib +/- Dexamethasone | N | N | 10252742 | OXALIPLATIN + MDG + PANITUMUMAB |
| 10008617 | 10005438 | 1.81 | 77.4 | Palliative (P) | 2018-12-07 | 2019-12-13 | Methotrexate High Dose (3g/m2) | 1 | N | 10252742 | ENZALUTAMIDE |
| 10008618 | 10007701 | 1.66 | 60 | Palliative (P) | 2017-07-18 | 2017-07-19 | PIXANTRONE | N | N | 10268360 | BORTEZOMIB |
| 10008619 | 10005443 | null | null | Disease modification (D) | 2017-11-07 | 2018-01-27 | Cyclophos + Dex + Lenalidomide | 02 | null | 10269868 | CHLORAMBUCIL |
| 10008620 | 10005446 | 1.71 | null | Disease modification (D) | 2019-02-17 | 2019-06-04 | NIVOLUMAB | 02 | N | 10271252 | LANREOTIDE |
| 10008621 | 10005451 | 1.86 | 101.85 | Disease modification (D) | 2017-04-04 | 2017-05-18 | FLAIR Trial | 2 | null | 10282430 | R-EPOCH |
| 10008622 | 10005453 | 1.76 | 60.2 | Disease modification (D) | 2019-04-27 | 2019-07-22 | ENRICH Trial | N | N | 10282870 | CHLORAMBUCIL + RITUXIMAB |
| 10008623 | 10005454 | 1.79 | 80.6 | Adjuvant (A) | 2017-08-11 | 2017-09-27 | FCR Oral - Cycle 2 onwards | 2 | N | 10284128 | HYDROXYCARBAMIDE |
| 10008624 | 10007708 | 1.71 | 0 | Palliative (P) | 2020-01-19 | 2020-02-03 | Cyclophosphamide oral | N | Y | 10286675 | CISPLATIN |
| 10008625 | 10005458 | 1.76 | 59.8 | Disease modification (D) | null | 2018-02-13 | Mitomycin Intravesical | null | N | 10320395 | CHLORAMBUCIL + RITUXIMAB |
| 10008626 | 10005460 | 1.79 | 72.7 | Not known (9) | 2018-07-25 | 2019-06-25 | DA-EPOCH-R | 2 | N | 10330137 | FCR |
| 10008627 | 10005463 | 1.83 | 95 | Palliative (P) | 2018-08-01 | 2019-04-20 | STAMPEDE TRIAL | 2 | N | 10336194 | TEMOZOLOMIDE + RT |
| 10008628 | 10005470 | null | 59.75 | Palliative (P) | 2017-08-27 | 2018-10-05 | Cyclophosphamide+Doce+Tras Main | N | N | 10349347 | PALBOCICLIB |
| 10008629 | 10005472 | 1.74 | 78.6 | Palliative (P) | 2017-06-29 | 2017-08-08 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 10363220 | VEMURAFENIB |
| 10008630 | 10007716 | 1.73 | 84 | null | 2018-05-05 | 2018-07-11 | Chlorambucil | 2 | N | 10369878 | ECX |
| 10008631 | 10005478 | null | 65 | Disease modification (D) | 2019-02-21 | 2019-03-03 | Cetuximab + Radiotherapy Load | 02 | N | 10370151 | SUNITINIB |
| 10008632 | 10007717 | 1.59 | 134 | Palliative (P) | 2017-03-29 | 2017-03-31 | ESHAP | N | N | 10372953 | CAPECITABINE + RT |
| 10008633 | 10005483 | 1.79 | null | Palliative (P) | 2019-02-13 | 2019-02-22 | Alemtuzumab | N | N | 10374253 | CETUXIMAB + IRINOTECAN + MDG |
| 10008634 | 10005485 | 1.74 | 78.7 | Palliative (P) | 2018-03-24 | 2018-03-28 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | N | 10377873 | ERLOTINIB |
| 10008635 | 10005488 | null | null | Neo-adjuvant (N) | 2020-04-28 | 2020-05-08 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10401494 | VENETOCLAX |
| 10008636 | 10005490 | 1.8 | 64 | Palliative (P) | 2016-11-26 | 2016-12-08 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 10403034 | DABRAFENIB + TRAMETINIB |
| 10008637 | 10005495 | 1.8 | 80 | Curative (C) | null | 2019-10-02 | Erlotinib | N | N | 10415778 | VEPEMB |
| 10008638 | 10005498 | 1.79 | 61.3 | Palliative (P) | 2017-12-19 | 2017-12-29 | IDARUBICIN | 01 | N | 10418698 | RUXOLITINIB |
| 10008639 | 10005501 | null | 66.5 | Palliative (P) | 2019-03-07 | 2019-03-21 | Cyclophosphamide High Dose | 02 | N | 10420706 | BORTEZOMIB |
| 10008640 | 10005505 | 1.64 | 72 | Curative (C) | 2019-01-30 | 2019-02-13 | Enzalutamide | 02 | N | 10421914 | CAPECITABINE + RT |
| 10008641 | 10005508 | 1.77 | 65 | Curative (C) | 2016-11-05 | 2016-11-19 | IVAC | 2 | N | 10422338 | TRIFLURIDINE + TIPIRACIL |
| 10008642 | 10005510 | 1.69 | 85.5 | Palliative (P) | 2016-11-22 | 2016-11-23 | FLUOROURACIL + MITOMYCIN | N | N | 10422820 | CISPLATIN + RT |
| 10008643 | 10005514 | 1.84 | null | Palliative (P) | 2017-11-19 | 2017-11-19 | ESHAP | N | N | 10424273 | THALIDOMIDE |
| 10008644 | 10005515 | 1.72 | 80 | Palliative (P) | 2017-12-07 | 2017-12-21 | Cabazitaxel | 02 | N | 10425028 | CISPLATIN + FLUOROURACIL |
| 10008645 | 10005517 | 1.68 | 76.3 | Palliative (P) | 2017-03-29 | 2017-04-27 | Cytarabine High Dose | N | N | 10425847 | IDELALISIB + RITUXIMAB |
| 10008646 | 10005520 | 1.8 | 92 | Palliative (P) | 2018-07-13 | 2018-07-29 | Cisplatin | N | N | 10429009 | DOCETAXEL + NINTEDANIB |
| 10008647 | 10007733 | 1.78 | 52.85 | Palliative (P) | 2018-12-23 | 2019-07-28 | Docetaxel + Gemcitabine with GCSF | 2 | N | 10429904 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10008648 | 10005522 | null | 85.5 | Disease modification (D) | 2017-12-17 | 2018-02-16 | Venetoclax | 2 | N | 10430552 | IDARUBICIN |
| 10008649 | 10005525 | 1.77 | 80 | Palliative (P) | 2018-03-15 | 2018-03-25 | Vinflunine | 2 | N | 10435336 | GEFITINIB |
| 10008650 | 10005529 | null | 53.9 | Palliative (P) | 2019-04-01 | 2019-05-07 | FEC 100 + DOCETAXEL + TRASTUZUMAB | 2 | N | 10437133 | CYCLOPHOSPHAMIDE |
| 10008651 | 10005530 | 1.75 | 94 | Curative (C) | 2015-12-23 | 2015-12-24 | Cetuximab + Radiotherapy Maint | N | N | 10439991 | CLADRIBINE |
| 10008652 | 10005531 | 1.54 | 84 | Palliative (P) | 2018-08-27 | 2018-08-27 | CARBOPLATIN + PACLITAXEL + RT | 1 | N | 10440812 | DOCETAXEL + NINTEDANIB |
| 10008653 | 10007739 | null | 110 | Curative (C) | 2017-12-06 | 2018-01-11 | CHLVPP | 1 | N | 10441739 | CAV |
| 10008654 | 10005536 | 1.8 | null | Curative (C) | 2019-07-24 | 2019-07-24 | AML16 DA 3+8 | N | null | 10445767 | ERLOTINIB |
| 10008655 | 10005542 | 1.62 | null | Palliative (P) | 2017-03-15 | 2017-03-27 | Pazopanib | N | N | 10451037 | FEC + DOCETAXEL |
| 10008656 | 10005548 | 1.76 | 89 | Palliative (P) | 2018-04-13 | 2018-06-25 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 10463889 | HYDROXYCARBAMIDE |
| 10008657 | 10005549 | 1.67 | 84 | Curative (C) | 2018-04-13 | 2018-04-14 | Ipilimumab | N | N | 10464205 | CHLORAMBUCIL + RITUXIMAB |
| 10008658 | 10005550 | 1.7 | 66 | Adjuvant (A) | 2015-10-10 | 2015-11-01 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 10466384 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10008659 | 10008685 | 164.5 | 86.7 | Adjuvant (A) | null | 2018-12-08 | PCV | 02 | N | 10475395 | CISPLATIN + ETOPOSIDE |
| 10008660 | 10005556 | 1.7 | 68 | Palliative (P) | 2019-02-09 | 2019-02-09 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 2 | null | 10476489 | VINORELBINE |
| 10008661 | 10005560 | 1.54 | 59.4 | Disease modification (D) | 2018-07-09 | 2018-12-11 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 10482233 | CISPLATIN + VINORELBINE |
| 10008662 | 10005561 | 1.8 | 96.1 | null | 2015-10-03 | 2015-10-15 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | N | 10482879 | NIVOLUMAB |